tailieunhanh - Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations

Despite the remarkable advances in the early diagnosis and treatment, overall 5-year survival rate of patients with pancreatic cancer is less than 10%. Gemcitabine (GEM), a cytidine nucleoside analogue and ribonucleotide reductase inhibitor, is a primary option for patients with advanced pancreatic cancer; however, its clinical efficacy is extremely limited. | Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN